Aldeyra Therapeutics, Inc.
Balance Sheet
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & Equivalents | $45.1M | $65.0M | $70.0M | $59.3M | $41.2M | $50.4M | $54.5M | $68.1M |
| Accounts Receivable | — | — | — | — | — | — | — | — |
| Inventory | — | — | — | — | — | — | — | — |
| Total Current Assets | $47.4M | $66.3M | $71.8M | $77.5M | $84.6M | $92.7M | $104.1M | $116.7M |
| Property, Plant & Equipment | $20.5K | — | $0 | — | — | — | $0 | $1.4K |
| Goodwill | — | — | — | — | — | — | — | — |
| Intangible Assets (Excl. Goodwill) | — | — | — | — | — | — | — | — |
| Total Assets | $47.5M | $66.5M | $72.1M | $77.8M | $85.0M | $93.2M | $104.6M | $117.3M |
| Liabilities | ||||||||
| Accounts Payable | $137.5K | $141.4K | $158.5K | $13.4K | $1.5M | $346.1K | $180.5K | $186.9K |
| Total Current Liabilities | $9.7M | $24.3M | $27.8M | $28.5M | $29.5M | $14.3M | $18.6M | $17.2M |
| Long-Term Debt | — | $0 | $0 | $0 | $0 | $15.1M | $15.0M | $15.0M |
| Total Liabilities | $9.7M | $24.3M | $27.8M | $28.6M | $29.7M | $29.6M | $33.6M | $32.2M |
| Stockholders' Equity | ||||||||
| Retained Earnings | $-492.9M | $-487.4M | $-484.0M | $-477.5M | $-469.8M | $-460.0M | $-450.1M | $-434.3M |
| Total Stockholders' Equity | $37.9M | $42.2M | $44.3M | $49.2M | $55.3M | $63.6M | $71.0M | $85.1M |